Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice

Inclusion Criteria:

• Participants ≥18 years of age with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PS), Crohn´s disease (CD), orulcerative colitis (UC)

• Participants must fulfill international and national guidelines for the use of abiologic disease-modifying antirheumatic drug (bDMARD) in RA, PsA, AS, PS, CD, or UC (chest X-ray and interferon gamma release assay (IGRA) or purified protein derivative (PPD) skin test negative for tuberculosis)

• In addition one of the following criteria must be fulfilled:

1. unsatisfactory DMARD response defined as treatment failure with at least twoDMARDs including methotrexate in participants with RA or PsA

2. unsatisfactory nonsteroidal anti-inflammatory drug (NSAID) response inparticipants with AS

3. unsatisfactory response to prior bDMARDs in participants with RA, PsA, or AS

4. unsatisfactory response to, contraindication to, or intolerance to other systemictherapy including cyclosporine, methotrexate, or psoralen with ultraviolet Alight (PUVA) in participants with PS

5. unsatisfactory response despite a full and adequate course of therapy with acorticosteroid and/or an immunosuppressant; or intolerance or medicalcontraindications for such therapies in CD

6. unsatisfactory response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or intolerance to or medicalcontraindications for such therapies in UC

Exclusion Criteria:

• Participants who are not covered in the latest version of the adalimumab Summary ofProduct Characteristics (SPC) for the syringe and pen

• Participants currently enrolled in another study program or clinical trial

• Participants who have been treated with adalimumab before